Zoetis (NYSE:ZTS) Stock Rating Reaffirmed by Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Zoetis (NYSE:ZTS) in a research report released on Wednesday morning, The Fly reports. The firm currently has a $130.00 price objective on the stock, up from their previous price objective of $116.00.

Other equities research analysts also recently issued reports about the company. Barclays initiated coverage on Zoetis in a report on Tuesday, June 11th. They set an overweight rating and a $120.00 target price for the company. Guggenheim initiated coverage on Zoetis in a report on Thursday, May 23rd. They set a buy rating and a $114.00 target price for the company. BMO Capital Markets upped their target price on Zoetis from $101.00 to $105.00 and gave the company a market perform rating in a report on Thursday, May 9th. Zacks Investment Research downgraded Zoetis from a buy rating to a hold rating in a report on Monday, May 6th. Finally, Gabelli downgraded Zoetis from a buy rating to a hold rating and set a $108.00 target price for the company. in a report on Thursday, May 2nd. They noted that the move was a valuation call. Six research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Zoetis has a consensus rating of Buy and a consensus target price of $106.67.

Shares of Zoetis stock opened at $110.79 on Wednesday. The company has a quick ratio of 2.79, a current ratio of 4.05 and a debt-to-equity ratio of 2.84. The firm has a market capitalization of $52.67 billion, a PE ratio of 35.40, a PEG ratio of 2.75 and a beta of 0.87. Zoetis has a fifty-two week low of $78.90 and a fifty-two week high of $112.25.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, May 2nd. The company reported $0.88 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.79 by $0.09. The business had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.45 billion. Zoetis had a return on equity of 73.66% and a net margin of 23.47%. The company’s revenue was up 6.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.75 earnings per share. Equities analysts anticipate that Zoetis will post 3.48 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 19th will be paid a $0.164 dividend. This represents a $0.66 annualized dividend and a yield of 0.59%. The ex-dividend date is Thursday, July 18th. Zoetis’s dividend payout ratio is currently 21.09%.

In related news, insider Roxanne Lagano sold 2,000 shares of the stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $101.89, for a total value of $203,780.00. Following the completion of the sale, the insider now directly owns 30,727 shares of the company’s stock, valued at approximately $3,130,774.03. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Clinton A. Jr. Lewis sold 6,124 shares of the stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $101.60, for a total value of $622,198.40. Following the completion of the sale, the executive vice president now directly owns 54,484 shares of the company’s stock, valued at $5,535,574.40. The disclosure for this sale can be found here. Over the last three months, insiders sold 70,591 shares of company stock valued at $7,214,549. Company insiders own 0.29% of the company’s stock.

A number of institutional investors have recently made changes to their positions in the stock. BlackRock Inc. lifted its stake in Zoetis by 2.2% in the 1st quarter. BlackRock Inc. now owns 37,486,408 shares of the company’s stock worth $3,773,759,000 after acquiring an additional 795,558 shares in the last quarter. Vanguard Group Inc lifted its stake in Zoetis by 0.8% in the 3rd quarter. Vanguard Group Inc now owns 35,947,496 shares of the company’s stock worth $3,291,353,000 after acquiring an additional 293,614 shares in the last quarter. Oregon Public Employees Retirement Fund lifted its stake in Zoetis by 9,042.7% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 14,335,563 shares of the company’s stock worth $168,000 after acquiring an additional 14,178,765 shares in the last quarter. Morgan Stanley lifted its stake in Zoetis by 0.9% in the 1st quarter. Morgan Stanley now owns 13,785,853 shares of the company’s stock worth $1,387,822,000 after acquiring an additional 127,988 shares in the last quarter. Finally, Polen Capital Management LLC increased its position in Zoetis by 1.9% in the 4th quarter. Polen Capital Management LLC now owns 9,553,567 shares of the company’s stock worth $817,212,000 after purchasing an additional 178,893 shares during the last quarter. 90.30% of the stock is owned by hedge funds and other institutional investors.

Zoetis Company Profile

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Recommended Story: Backdoor Roth IRA Conversion and Strategy

The Fly

Analyst Recommendations for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.